Vakaramoko "Karam" Diaby,
Adjunct Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 273-6268
Business Email:
v.diaby@ufl.edu
Teaching Profile
Courses Taught
2017-2023
PHA7979 Advanced Research
2019-2023
PHA7980 Research for Doctoral Dissertation
2019-2024
PHA6935 Selected Topics in Pharmacy
2018,2020-2021
PHA6910 Supervised Research
2020-2021
PHA6806 Pharmacoeconomic Modeling
2018-2021
PHA5876C Pt Care 8 Complex Pts
2021
PHA5787 Pharmacotherapy 5
2018-2019,2021
PHA5787C Pt Care 5: Endo
2018-2019,2021
PHA5784C Pt Care 4: GI and Renal
2018-2021
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021
PHA6937 Topics in Pharmaceutical Administration
2021
PHA6940 Supervised Teaching
2018,2020-2021
PHA6971 Research for Master’s Thesis
2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2018-2020
PHA6286 Pharmaceutical Microeconomics
2018-2020
PHA6287 Pharmaceutical Health Economics
Publications
Academic Articles
2025
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States.
Journal of managed care & specialty pharmacy.
31(1):60-67
[DOI] 10.18553/jmcp.2025.31.1.60.
[PMID] 39745847.
2025
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States.
Journal of managed care & specialty pharmacy.
31(1):53-59
[DOI] 10.18553/jmcp.2025.31.1.53.
[PMID] 39745838.
2024
A bibliometric analysis and typology of drug pricing policies across the globe.
Medicine.
103(42)
[DOI] 10.1097/MD.0000000000040112.
[PMID] 39432601.
2024
Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
British journal of cancer.
130(12):1943-1950
[DOI] 10.1038/s41416-024-02680-0.
[PMID] 38637603.
2024
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors.
Breast cancer research and treatment.
204(3):561-577
[DOI] 10.1007/s10549-023-07205-6.
[PMID] 38191684.
2024
Economic Burden of Medically Attended Respiratory Syncytial Virus Infections Among Privately Insured Children Under 5 Years of Age in the USA.
Influenza and other respiratory viruses.
18(7)
[DOI] 10.1111/irv.13347.
[PMID] 38951044.
2024
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework.
PharmacoEconomics.
42(Suppl 2):211-224
[DOI] 10.1007/s40273-024-01392-w.
[PMID] 38758291.
2024
Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation.
Drug safety.
[DOI] 10.1007/s40264-024-01488-4.
[PMID] 39499480.
2024
Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018.
Pharmacotherapy.
44(9):701-710
[DOI] 10.1002/phar.4604.
[PMID] 39239761.
2023
Application of Machine Learning Algorithms to Predict Uncontrolled Diabetes Using the All of Us Research Program Data.
Healthcare (Basel, Switzerland).
11(8)
[DOI] 10.3390/healthcare11081138.
[PMID] 37107973.
2023
Development and validation of a tool to predict high-need, high-cost patients hospitalised with ischaemic heart disease.
BMJ open.
13(9)
[DOI] 10.1136/bmjopen-2023-073485.
[PMID] 37751949.
2023
Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.
American journal of preventive medicine.
64(1):96-104
[DOI] 10.1016/j.amepre.2022.08.016.
[PMID] 36257884.
2023
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study.
Pharmacotherapy.
43(9):883-893
[DOI] 10.1002/phar.2841.
[PMID] 37381584.
2023
Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer’s and related dementias from 2010 to 2015.
Expert review of pharmacoeconomics & outcomes research.
23(5):555-559
[DOI] 10.1080/14737167.2023.2195628.
[PMID] 36974630.
2023
Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression.
Journal of managed care & specialty pharmacy.
29(4):431-445
[DOI] 10.18553/jmcp.2023.29.4.431.
[PMID] 36989452.
2022
An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines.
Clinical drug investigation.
42(5):377-390
[DOI] 10.1007/s40261-022-01155-5.
[PMID] 35488964.
2022
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.
Expert review of pharmacoeconomics & outcomes research.
22(5):735-741
[DOI] 10.1080/14737167.2022.2044309.
[PMID] 35189767.
2022
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.
Clinical drug investigation.
42(6):501-511
[DOI] 10.1007/s40261-022-01160-8.
[PMID] 35614298.
2022
Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation.
Expert review of pharmacoeconomics & outcomes research.
22(2):247-258
[DOI] 10.1080/14737167.2021.1914593.
[PMID] 33827359.
2022
Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
JCO oncology practice.
18(1):e163-e174
[DOI] 10.1200/OP.21.00140.
[PMID] 34228489.
2022
Predictors of 30-day readmission and hospitalization costs of patients with hepatic encephalopathy in the US from 2010 to 2014.
Expert review of pharmacoeconomics & outcomes research.
22(3):409-415
[DOI] 10.1080/14737167.2021.1927717.
[PMID] 33985399.
2022
Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States.
The pharmacogenomics journal.
22(4):223-229
[DOI] 10.1038/s41397-022-00277-5.
[PMID] 35436997.
2022
RSV testing practice and positivity by patient demographics in the United States: integrated analyses of MarketScan and NREVSS databases.
BMC infectious diseases.
22(1)
[DOI] 10.1186/s12879-022-07659-x.
[PMID] 35941563.
2021
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Expert review of pharmacoeconomics & outcomes research.
21(1):159-168
[DOI] 10.1080/14737167.2021.1851600.
[PMID] 33186061.
2021
Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.
American journal of preventive medicine.
61(4):576-584
[DOI] 10.1016/j.amepre.2021.04.013.
[PMID] 34210584.
2021
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review.
Expert review of pharmacoeconomics & outcomes research.
21(5):923-941
[DOI] 10.1080/14737167.2021.1913056.
[PMID] 33934691.
2021
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Expert review of pharmacoeconomics & outcomes research.
21(3):353-364
[DOI] 10.1080/14737167.2021.1848553.
[PMID] 33213205.
2021
Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
17(5):939-946
[DOI] 10.1016/j.soard.2021.01.025.
[PMID] 33648887.
2021
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Journal of managed care & specialty pharmacy.
27(10):1388-1402
[DOI] 10.18553/jmcp.2021.27.10.1388.
[PMID] 34595949.
2021
Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach.
Expert review of pharmacoeconomics & outcomes research.
21(5):1043-1048
[DOI] 10.1080/14737167.2021.1842200.
[PMID] 33131344.
2021
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions
Journal Of Managed Care & Specialty Pharmacy.
S24-S31
[DOI] 10.18553/jmcp.2021.27.9-a.s24.
[PMID] 34534006.
2021
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions.
Journal of managed care & specialty pharmacy.
27(9-a Suppl):S22-S29
[DOI] 10.18553/jmcp.2021.27.9-a.s22.
[PMID] 34579542.
2021
Prevalence and effects of suicidal ideation diagnosis code position in claims on readmission rate estimates.
Research in social & administrative pharmacy : RSAP.
17(6):1174-1180
[DOI] 10.1016/j.sapharm.2020.09.003.
[PMID] 32928656.
2020
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
Breast (Edinburgh, Scotland).
49:141-148
[DOI] 10.1016/j.breast.2019.11.012.
[PMID] 31805500.
2020
A quantitative analysis of the effect of continuity of care on 30-day readmission and in-hospital mortality among patients with acute ischemic stroke.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
29(9)
[DOI] 10.1016/j.jstrokecerebrovasdis.2020.105053.
[PMID] 32807459.
2020
Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
Journal of managed care & specialty pharmacy.
26(2)
[DOI] 10.18553/jmcp.2020.26.2.221.
[PMID] 32011959.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2020
Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases.
Applied health economics and health policy.
18(5):679-687
[DOI] 10.1007/s40258-020-00560-1.
[PMID] 32157631.
2020
Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting.
Data in brief.
29
[DOI] 10.1016/j.dib.2020.105194.
[PMID] 32071975.
2020
Examining factors associated with adherence to hormonal therapy in breast cancer patients.
Research in social & administrative pharmacy : RSAP.
16(4):574-582
[DOI] 10.1016/j.sapharm.2019.08.005.
[PMID] 31473108.
2020
In our war against the opioid epidemic, could ‘weed’ be a winner?
Expert review of pharmacoeconomics & outcomes research.
20(5):423-429
[DOI] 10.1080/14737167.2020.1807944.
[PMID] 32799573.
2020
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Clinical and translational science.
13(2):352-361
[DOI] 10.1111/cts.12719.
[PMID] 32053288.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER-2 Negative Metastatic Breast Cancer: A commentary
Journal Of Managed Care & Specialty Pharmacy.
2020
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary.
Journal of managed care & specialty pharmacy.
26(7):826-831
[DOI] 10.18553/jmcp.2020.26.7.826.
[PMID] 32584682.
2020
Self-assessed life expectancy among older adults in Côte d’Ivoire.
BMC public health.
20(1)
[DOI] 10.1186/s12889-020-09034-4.
[PMID] 32539697.
2020
Timing, Costs, and Survival Outcome of Specialty Palliative Care in Medicare Beneficiaries With Metastatic Non-Small-Cell Lung Cancer.
JCO oncology practice.
16(12):e1532-e1542
[DOI] 10.1200/OP.20.00298.
[PMID] 33006914.
2020
Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.
Research in social & administrative pharmacy : RSAP.
16(8):1095-1099
[DOI] 10.1016/j.sapharm.2019.11.009.
[PMID] 31753693.
2019
Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data.
Cancer medicine.
8(1):117-127
[DOI] 10.1002/cam4.1904.
[PMID] 30548840.
2019
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
22(11):1283-1288
[DOI] 10.1016/j.jval.2019.06.014.
[PMID] 31708065.
2019
Value Assessment Frameworks in the United States: A Call for Patient Engagement.
PharmacoEconomics – open.
3(1):1-3
[DOI] 10.1007/s41669-018-0094-z.
[PMID] 30182346.
2018
An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
Current diabetes reviews.
14(4):363-375
[DOI] 10.2174/1573399813666170724113240.
[PMID] 28738763.
2018
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Journal of managed care & specialty pharmacy.
24(2):142-152
[DOI] 10.18553/jmcp.2018.24.2.142.
[PMID] 29384027.
2018
Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review.
PharmacoEconomics – open.
2(4):359-369
[DOI] 10.1007/s41669-018-0070-7.
[PMID] 29470807.
2017
Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy.
Current medical research and opinion.
33(2):391-400
[DOI] 10.1080/03007995.2016.1257983.
[PMID] 27819160.
2017
Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Breast cancer research and treatment.
166(3):951-963
[DOI] 10.1007/s10549-017-4473-4.
[PMID] 28840424.
2016
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
Breast cancer research and treatment.
160(1):187-196
[PMID] 27654970.
2016
ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare.
Expert review of pharmacoeconomics & outcomes research.
16(1):141-7
[DOI] 10.1586/14737167.2015.1083863.
[PMID] 26361235.
2016
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients.
Current medical research and opinion.
32(6):991-6
[DOI] 10.1185/03007995.2016.1149056.
[PMID] 26824145.
2016
Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
PloS one.
11(9)
[DOI] 10.1371/journal.pone.0162951.
[PMID] 27648831.
2015
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Breast cancer research and treatment.
151(1):27-40
[DOI] 10.1007/s10549-015-3383-6.
[PMID] 25893588.
2015
Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis.
Health expectations : an international journal of public participation in health care and health policy.
18(6):1894-905
[DOI] 10.1111/hex.12287.
[PMID] 25327341.
2015
Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation
Pharmaceutical Medicine.
29(5):247-253
[DOI] 10.1007/s40290-015-0113-7.
2015
Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion.
Expert review of pharmacoeconomics & outcomes research.
15(1):13-9
[DOI] 10.1586/14737167.2015.965155.
[PMID] 25267699.
2015
Multicriteria decision analysis in oncology.
Health expectations : an international journal of public participation in health care and health policy.
18(6):1812-26
[DOI] 10.1111/hex.12178.
[PMID] 24635949.
2015
Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective.
Drugs & aging.
32(4):305-14
[DOI] 10.1007/s40266-015-0251-3.
[PMID] 25825121.
2014
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
Breast cancer research and treatment.
147(2):433-41
[DOI] 10.1007/s10549-014-3042-3.
[PMID] 25012857.
2014
How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide.
Expert review of pharmacoeconomics & outcomes research.
14(1):81-99
[DOI] 10.1586/14737167.2014.859525.
[PMID] 24328890.
2014
Re: Xie J, Diener M, De G, et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ 2014;16(2):278-88.
Journal of medical economics.
17(4):248-9
[DOI] 10.3111/13696998.2014.892883.
[PMID] 24506762.
2014
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
PharmacoEconomics.
32(2):101-8
[DOI] 10.1007/s40273-013-0123-9.
[PMID] 24338265.
2014
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial.
Breast cancer research and treatment.
146(3):669-73
[DOI] 10.1007/s10549-014-3047-y.
[PMID] 25017612.
2013
Exploring the state of pharmacy profession: The perspective of Côte d’Ivoire
Currents in Pharmacy Teaching and Learning.
5(5):470-476
[DOI] 10.1016/j.cptl.2013.06.005.
2013
Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?
Best practice & research. Clinical gastroenterology.
27(6):831-44
[DOI] 10.1016/j.bpg.2013.08.016.
[PMID] 24182604.
2013
Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis
Operational Research.
2(1):20-24
[DOI] 10.1016/j.orhc.2013.03.001.
2013
Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers.
International journal of technology assessment in health care.
29(4):456-65
[DOI] 10.1017/S0266462313000573.
[PMID] 24290340.
2011
A Proposed Framework for Formulary Listing in Low-Income Countries
Pharmaceutical Medicine.
25(2):71-82
[DOI] 10.1007/BF03256848.
2011
An application of a proposed framework for formulary listing in low-income countries: the case of Côte d’Ivoire.
Applied health economics and health policy.
9(6):389-402
[DOI] 10.2165/11595220-000000000-00000.
[PMID] 22017499.
2011
Eliciting preferences for reimbursed drugs selection criteria in Côte d’Ivoire.
The patient.
4(2):125-31
[DOI] 10.2165/11586060-000000000-00000.
[PMID] 21766901.
2007
Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Maturitas.
58(2):138-49
[PMID] 17870259.
Grants
Mar 2021
– Jun 2021
Incorporating Health Equity into Value Assessment: Frameworks, Promising Alternatives, and Future Directions
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Jan 2021
– Jun 2021
Racial and Ethnic Disparities in Medication Utilization and Adherence
Role: Principal Investigator
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Jan 2020
– Dec 2020
ECONOMIC EVALUATION OF RAPID WHOLE GENOME SEQUENCING (rWGS) IN CRITICALLY ILL CHILDREN AND ADOLESCENTS: THE CASE OF THE NICKLAUS CHILDRENS HOSPITAL
Role: Principal Investigator
Funding: VARIETY CHILDRENS HOSP DBA NICKLAUS
Sep 2016
– Sep 2022
Southeastern and Coastal Center for Agricultural Health and Safety (SCC-AHS)
Role: Project Manager
Funding: CTRS FOR DIS CNTRL INST OCCUP SFTY HLTH
Contact Details
Phones:
- Business:
- (352) 273-6268
Emails:
- Business:
- v.diaby@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100496
GAINESVILLE FL 32610